140 related articles for article (PubMed ID: 28025100)
1. ARF6, induced by mutant Kras, promotes proliferation and Warburg effect in pancreatic cancer.
Liang C; Qin Y; Zhang B; Ji S; Shi S; Xu W; Liu J; Xiang J; Liang D; Hu Q; Ni Q; Yu X; Xu J
Cancer Lett; 2017 Mar; 388():303-311. PubMed ID: 28025100
[TBL] [Abstract][Full Text] [Related]
2. ARF6 and AMAP1 are major targets of
Hashimoto S; Furukawa S; Hashimoto A; Tsutaho A; Fukao A; Sakamura Y; Parajuli G; Onodera Y; Otsuka Y; Handa H; Oikawa T; Hata S; Nishikawa Y; Mizukami Y; Kodama Y; Murakami M; Fujiwara T; Hirano S; Sabe H
Proc Natl Acad Sci U S A; 2019 Aug; 116(35):17450-17459. PubMed ID: 31399545
[TBL] [Abstract][Full Text] [Related]
3. Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells.
Ye Z; Hu Q; Zhuo Q; Zhu Y; Fan G; Liu M; Sun Q; Zhang Z; Liu W; Xu W; Ji S; Yu X; Xu X; Qin Y
Am J Cancer Res; 2020; 10(4):1182-1193. PubMed ID: 32368394
[TBL] [Abstract][Full Text] [Related]
4. Roles of Arf6 in cancer cell invasion, metastasis and proliferation.
Li R; Peng C; Zhang X; Wu Y; Pan S; Xiao Y
Life Sci; 2017 Aug; 182():80-84. PubMed ID: 28625359
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma.
Liang C; Qin Y; Zhang B; Ji S; Shi S; Xu W; Liu J; Xiang J; Liang D; Hu Q; Ni Q; Xu J; Yu X
Mol Cancer Res; 2017 Feb; 15(2):201-212. PubMed ID: 28108627
[TBL] [Abstract][Full Text] [Related]
6. ADP-Ribosylation Factor 6 Pathway Acts as a Key Executor of Mesenchymal Tumor Plasticity.
Hashimoto A; Hashimoto S
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834383
[TBL] [Abstract][Full Text] [Related]
7. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
8. Integrin β6 acts as an unfavorable prognostic indicator and promotes cellular malignant behaviors via ERK-ETS1 pathway in pancreatic ductal adenocarcinoma (PDAC).
Li Z; Lin P; Gao C; Peng C; Liu S; Gao H; Wang B; Wang J; Niu J; Niu W
Tumour Biol; 2016 Apr; 37(4):5117-31. PubMed ID: 26547582
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
Liao J; Hwang SH; Li H; Yang Y; Yang J; Wecksler AT; Liu JY; Hammock BD; Yang GY
Cancer Lett; 2016 Feb; 371(2):187-93. PubMed ID: 26683769
[TBL] [Abstract][Full Text] [Related]
10. ARHGEF15 overexpression worsens the prognosis in patients with pancreatic ductal adenocarcinoma through enhancing the motility and proliferative activity of the cancer cells.
Fukushima H; Yasumoto M; Ogasawara S; Akiba J; Kitasato Y; Nakayama M; Naito Y; Ishida Y; Okabe Y; Yasunaga M; Horiuchi H; Sakamoto E; Itadani H; Mizuarai S; Oie S; Yano H
Mol Cancer; 2016 May; 15(1):32. PubMed ID: 27145964
[TBL] [Abstract][Full Text] [Related]
11. The GTPase ARF6 Controls ROS Production to Mediate Angiotensin II-Induced Vascular Smooth Muscle Cell Proliferation.
Bourmoum M; Charles R; Claing A
PLoS One; 2016; 11(1):e0148097. PubMed ID: 26824355
[TBL] [Abstract][Full Text] [Related]
12. Adenosine diphosphate-ribosylation factor 6 is required for epidermal growth factor-induced glioblastoma cell proliferation.
Li M; Wang J; Ng SS; Chan CY; He ML; Yu F; Lai L; Shi C; Chen Y; Yew DT; Kung HF; Lin MC
Cancer; 2009 Nov; 115(21):4959-72. PubMed ID: 19642173
[TBL] [Abstract][Full Text] [Related]
13. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
Kong B; Wu W; Cheng T; Schlitter AM; Qian C; Bruns P; Jian Z; Jäger C; Regel I; Raulefs S; Behler N; Irmler M; Beckers J; Friess H; Erkan M; Siveke JT; Tannapfel A; Hahn SA; Theis FJ; Esposito I; Kleeff J; Michalski CW
Gut; 2016 Apr; 65(4):647-57. PubMed ID: 25601637
[TBL] [Abstract][Full Text] [Related]
14. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
15. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
[TBL] [Abstract][Full Text] [Related]
16. Arf6 promotes cell proliferation via the PLD-mTORC1 and p38MAPK pathways.
Knizhnik AV; Kovaleva OV; Komelkov AV; Trukhanova LS; Rybko VA; Zborovskaya IB; Tchevkina EM
J Cell Biochem; 2012 Jan; 113(1):360-71. PubMed ID: 21928324
[TBL] [Abstract][Full Text] [Related]
17. The multifunctional growth factor midkine promotes proliferation and migration in pancreatic cancer.
Rawnaq T; Dietrich L; Wolters-Eisfeld G; Uzunoglu FG; Vashist YK; Bachmann K; Simon R; Izbicki JR; Bockhorn M; Güngör C
Mol Cancer Res; 2014 May; 12(5):670-80. PubMed ID: 24567526
[TBL] [Abstract][Full Text] [Related]
18. Critical role of oncogenic KRAS in pancreatic cancer (Review).
Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
[TBL] [Abstract][Full Text] [Related]
19. ADP-ribosylation factor 6 regulates tumorigenic and invasive properties in vivo.
Muralidharan-Chari V; Hoover H; Clancy J; Schweitzer J; Suckow MA; Schroeder V; Castellino FJ; Schorey JS; D'Souza-Schorey C
Cancer Res; 2009 Mar; 69(6):2201-9. PubMed ID: 19276388
[TBL] [Abstract][Full Text] [Related]
20. Abrogation of ARF6 in promoting erastin-induced ferroptosis and mitigating capecitabine resistance in gastric cancer cells.
Geng D; Wu H
J Gastrointest Oncol; 2022 Jun; 13(3):958-967. PubMed ID: 35837166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
